Parsing NJ Court's Rationale For Denying Lipitor Class Cert.

On June 6, a motion for summary judgment was granted in In re: Lipitor Antitrust Litigation, dismissing claims of a pay-for-delay settlement from Pfizer Inc., the manufacturer of Lipitor, to Ranbaxy.

The plaintiffs alleged that Pfizer entered into a reverse payment agreement with Ranbaxy to delay its launch of generic Lipitor, a cholesterol medication.

Read more in this piece, which was recently published in Law360.